MONMOUTH JUNCTION, N.J.,
May 24, 2017 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a critical care
immunotherapy leader using CytoSorb® blood purification to treat
deadly inflammation in critically-ill and cardiac surgery patients
around the world, announced that its CEO and CFO were selected to
speak at two separate conferences later today.
2017 Special Operations Medical Association Scientific Assembly
(SOMSA)
Presenter: Dr. Phillip Chan MD, PhD, CEO
Talk: "Development of New Treatments for Severe
Hyperkalemia in Austere Conditions
Where: Charlotte
Convention Center, Charlotte, North
Carolina
When: Wednesday, May 24,
2017 at 1:45 PM PDT
Presentation Room: 207CD
Dr. Chan was invited to speak on the development of new
potassium lowering technologies that utilize novel
potassium-binding sorbents to treat severe hyperkalemia, a
potentially life-threatening elevation of potassium in the blood
that can occur as a result of severe trauma, burn injury, and
tissue ischemia. These strategies were specifically designed
to be used to stabilize our wounded warfighters in austere
battlefield environments, where delays in evacuation necessitate
prolonged field care for up to 72 hours before they can be brought
to definitive care. U.S. Special Operations Command (SOCOM)
synchronizes the planning of Special Operations and provides
Special Operations Forces to support persistent, networked, and
distributed Global Combatant Command operations in order to protect
and advance our Nation's interests. This work was funded
through two Small Business Innovation Research (SBIR) contracts by
the U.S. Army Medical Research and Materiel Command
(USAMRMC).
18th Annual B. Riley & Co. Investor
Conference
Presenter: Kathleen Bloch, CFO
Where: Loews Santa Monica Beach Hotel, 1700 Ocean
Avenue, Santa Monica, CA
When: Wednesday, May 24,
2017 at 3:00PM PDT
Presentation Room: Arcadia D
Ms. Bloch will be meeting with investors in one-on-one meetings
during the two day conference (May
24-25th). A copy of the presentation will
be available on the company's investor relations website.
About CytoSorbents Corporation (NASDAQ:
CTSO)
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its flagship
product, CytoSorb® is approved in the European Union with
distribution in 43 countries around the world, as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" or "cytokine release syndrome" that could
otherwise cause massive inflammation, organ failure and death in
common critical illnesses such as sepsis, burn injury, trauma, lung
injury and pancreatitis, as well as in cancer immunotherapy. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb® is also being used during and
after cardiac surgery to remove inflammatory mediators, such as
cytokines and free hemoglobin, which can lead to post-operative
complications, including multiple organ failure. CytoSorbents has
completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a
multi-center, randomized controlled study that has demonstrated the
safety and efficacy of free hemoglobin reduction with
intra-operative CytoSorb® use in a heart-lung machine during
complex cardiac surgery. In 2017, the company plans to
initiate a pivotal REFRESH 2 trial intended to support U.S. FDA
approval. CytoSorb® has been used safely in more than 23,000
human treatments to date.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding in excess of $18
million from DARPA, the U.S. Army, the U.S. Department of
Health and Human Services, the National Institutes of Health (NIH),
National Heart, Lung, and Blood Institute (NHLBI), U.S. Special
Operations Command (SOCOM) and others. The Company has numerous
products under development based upon this unique blood
purification technology, protected by 32 issued U.S. patents and
multiple applications pending, including CytoSorb-XL, HemoDefend™,
VetResQ™, ContrastSorb, DrugSorb, and others. For more
information, please visit the Company's websites at
www.cytosorbents.com and www.cytosorb.com or follow
us on Facebook and Twitter
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 3, 2017, as updated by the risks reported in
our Quarterly Reports on Form 10-Q, and in the press releases and
other communications to shareholders issued by us from time to time
which attempt to advise interested parties of the risks and factors
which may affect our business. We caution you not to place undue
reliance upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow Us
on Facebook and Twitter
Cytosorbents Contact:
Amy
Vogel
Investor Relations
(732) 398-5394
avogel@cytosorbents.com
Public Relations Contact:
Amy
Phillips
Pascale Communications
412-327-9499
amy@pascalecommunications.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-selected-to-present-at-special-operations-somsa-2017-conference-and-18th-annual-b-riley--co-investor-conference-300463018.html
SOURCE CytoSorbents Corporation